A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2016-05-20
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of rituximab in combination with
fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line
treatment of participants with CLL.